Trotana Therapeutics
3 known investors
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Also known as Trotana · Trotana, Inc.
Investors · 3
Company profile
researched Aug 2026Trotana Therapeutics (Trotana, Inc.) is a San Diego, California biotechnology company focused on the discovery and development of medicines that target RNA binding proteins. Its stated program emphasis is novel oral anti-inflammatory small molecule therapeutics intended for chronic inflammatory diseases and a broader set of indications with unmet need, with an aim of improved efficacy and safety relative to existing options.
Sources place the company in Sorrento Valley / 5555 Oberlin Dr, San Diego 92121, and date its founding to 2019. Reported co-founders are Gene Yeo, described as a researcher in RNA biology and therapeutics, and Frank Furnari. The company remains private and preclinical in the material available; no pipeline candidates, clinical trials, or partnerships are described in the sources.
Employee-count reporting is inconsistent across aggregators: one profile states 11-50 employees (last updated September 2025) while another states 1001-5000, a range that is inconsistent with the company's stated stage and funding.
Founding story
According to an aggregator profile, Trotana was co-founded in 2019 by Gene Yeo, a researcher in RNA biology and therapeutics, and Frank Furnari, with the intent of translating research on RNA binding proteins into therapies. The company's own description states that its founders are leaders in the field of RNA binding proteins and that Trotana was launched to provide new therapies for unmet needs across a variety of indications.
Business model
Trotana is described as a therapeutics developer, discovering and optimizing small molecule drug candidates in-house rather than selling a commercial product; the sources describe no revenue-generating operations and indicate it is privately held and venture-funded.
Traction
Reported traction is limited to financing: a $53.0M Series A dated January 2025 and prior venture backing described as seed funding. No pipeline milestones, clinical data, partnerships, or commercial metrics are reported in the sources.
Latest developments
The most recent items in the sources are a $53.0M Series A reported for January 2025 with Canaan Partners and Lightstone Ventures, and the addition of Medical Excellence Capital to the investor list with a date of September 2025. A company-directory profile last showed activity on 23 September 2025 and listed the company as active.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned by secondary sources within RNA-targeted drug discovery and the market for oral anti-inflammatory therapeutics. No revenue, market share, pipeline stage, or competitive ranking data appear in the sources.
The aggregator profiles attribute differentiation to the targeting of RNA binding proteins, described as a relatively unexplored therapeutic mechanism, to founder expertise in RNA biology, to an oral route of administration for anti-inflammatory therapy, to venture backing from established life-science investors, and to a San Diego location within a biotech cluster. These claims come from a secondary aggregator rather than primary company disclosure.
Technology
Discovery and development of medicines targeting RNA binding proteins, modulating RNA-protein interactions. Secondary descriptions indicate small molecule therapeutics designed for oral administration and reference the use of biological insight in RNA biology and computational methods to identify and optimize candidates; the sources do not describe a named platform or specific targets.
Go-to-market
Patients with chronic inflammatory conditions and other indications of unmet need, and the healthcare providers treating them, as described in secondary profiles.
Geography
Single reported location in San Diego, California, United States, cited as 5555 Oberlin Dr, San Diego, CA 92121 and as the Sorrento Valley area.
History
The company was founded in 2019 in San Diego. Investor records list ARCH Venture Partners (dated March 2022), Lightstone Ventures (dated December 2021) and Medical Excellence Capital (dated September 2025) among its backers, with one aggregator describing the earlier capital as seed venture funding. A $53.0M Series A involving Canaan Partners and Lightstone Ventures is reported for January 2025. One profile lists the company as private with no IPO.
Risks & controversies
Available information is limited and partly inconsistent: employee counts differ substantially between aggregator profiles (11-50 versus 1001-5000), and investor lists differ (one source names Canaan Partners and Lightstone Ventures for the Series A, another lists ARCH Venture Partners, Lightstone Ventures and Medical Excellence Capital). Most details derive from secondary data aggregators rather than primary company or regulatory filings. No clinical or preclinical data are disclosed in the sources.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsSeries A round reported at $53.0M with participation from Canaan Partners and Lightstone Ventures; no lead investor listed.
$53M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 6
primary sources listed
- Trotana Therapeutics: Funding, Team & Investorsstartupintros.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Trotana Therapeutics do?
- San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
- Who are Trotana Therapeutics's investors?
- Trotana Therapeutics's investors include ARCH Venture Partners, Lightstone Ventures, Medical Excellence Capital.